重新评估HR+/HER2-乳腺癌的预后差异：CDK4/6抑制剂的未解释影响

{"title":"重新评估HR+/HER2-乳腺癌的预后差异：CDK4/6抑制剂的未解释影响","authors":"Arif Hakan Önder","doi":"10.1016/j.breast.2025.104462","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":9093,"journal":{"name":"Breast","volume":"81 ","pages":"Article 104462"},"PeriodicalIF":5.7000,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Reevaluating prognostic differences in HR+/HER2− Breast Cancer: The unaccounted impact of CDK4/6 inhibitors\",\"authors\":\"Arif Hakan Önder\",\"doi\":\"10.1016/j.breast.2025.104462\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":9093,\"journal\":{\"name\":\"Breast\",\"volume\":\"81 \",\"pages\":\"Article 104462\"},\"PeriodicalIF\":5.7000,\"publicationDate\":\"2025-03-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Breast\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0960977625004795\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"OBSTETRICS & GYNECOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0960977625004795","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}